China Resources Double-Crane Pharmaceutical announced that its wholly-owned subsidiary, China Resources Purple Bamboo Pharmaceutical Co., Ltd., has received the ZP36 'Drug Clinical Trial Approval Letter' issued by the National Medical Products Administration. ZP36 is used to treat various functional disorders caused by progesterone deficiency, including menstrual disorders, dysmenorrhea, premenstrual syndrome, etc.
华润双鹤：ZP36获得临床试验批准通知书
China Resources Double-Crane Pharmaceutical: ZP36 has received the clinical trial approval letter.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.